Corporate & Investor Presentation

Reconciliation of non-GAAP financial measures, cont'd The measure "non-GAAP income from operations" is reconciled with GAAP income from operations below: (Unaudited; $ in thousands, except for per share amounts) 0000 Three Months Ended Nine Months Ended March 31, 2021 March 31, 2020 March 31, 2021 March 31, 2020 GAAP income from operations $ Amortization of acquired intangibles - cost of sales (A) Amortization of acquired intangibles - operating 223,426 10,924 7,445 $ 217,500 12,136 8,272 $ SA 662,040 $ 586,412 34,066 37,623 23,377 21,872 expenses (A) Restructuring - cost of sales (A) 5,232 - Restructuring operating expenses (A) 8,673 Deferred revenue fair value adjustment (A) Litigation settlement expenses (A) Non-GAAP income from operations $ 241,795 $ SA 2,102 (600) 237,908 $ 733,388 $ 647,409 (A) ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses, deferred revenue fair value adjustment, litigation settlement expenses, the (gain) loss on equity investments and the fair value impairment of investment from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. 37 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed

View entire presentation